GLP-1 drugs comparison
EndocrinologyCompare GLP-1 receptor agonists for type 2 diabetes and weight management. These drugs have become some of the most prescribed (and most denied) medications in the U.S. Coverage varies dramatically between diabetes and weight loss indications.
Select any two to compare side by side
All products in this comparison
| Product | Manufacturer | Route | Frequency | Key difference |
|---|---|---|---|---|
| Ozempic | Novo Nordisk | SC injection | Weekly | Most prescribed GLP-1 for T2D; semaglutide; cardiovascular benefit data |
| Wegovy | Novo Nordisk | SC injection | Weekly | Higher-dose semaglutide for chronic weight management; FDA-approved for obesity |
| Mounjaro | Eli Lilly | SC injection | Weekly | Dual GIP/GLP-1 agonist (tirzepatide); superior A1C and weight reduction |
| Zepbound | Eli Lilly | SC injection | Weekly | Tirzepatide for chronic weight management; FDA-approved for obesity |
| Rybelsus | Novo Nordisk | Oral (tablet) | Daily | Only oral GLP-1; taken on empty stomach; semaglutide |
Related guides
Denied one of these medications?
Ellen can decode your denial letter, identify why you were denied, and generate a personalized appeal, free for patients.